Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19
Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19
Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19.
Update from the International Guillain–Barré Syndrome Outcome Study (IGOS)
Diagnosis and management of Guillain–Barré syndrome in ten steps Portuguese Spanish Chinese Nature Reviews Neurology: https://www.nature.com/articles/s41582-019-0250-9; Published Sept 20, 2019. Explanation of the above referenced article below.https://creativecommons.org/licenses/by/4.0/ Authors: Sonja Leonhard, Melissa Mandarakas, Francisco de Assis Aquino Gondim, Kathleen Bateman, Maria Lúcia Ferreira, David Cornblath, Pieter van Doorn, Mario Dourado, Richard Hughes, Badrul Islam, S Kusunoki, Carlos Pardo, Ricardo Reisin, Jim…
Now Accepting Applications for 2020 Research Grants
As part of the GBS|CIDP Foundation International’s mission to provide education and support research, we offer research grants to qualified applicants.
New Research Grant Announced: Exploring possible role of TGR5 and FXR in autoimmune neuropathy
Please join us in congratulating, 2019 GBS|CIDP Research Grant Recipient, Betty Soliven, MD for her study: Exploring the possible role of TGR5 and FXR in autoimmune neuropathy Betty Soliven, MD is a Professor and the Associate Chair for Faculty Affairs of the Department of Neurology at the University of Chicago Synopsis There is increasing evidence…
Please join us in Congratulating 2019 GBS|CIDP Foundation Research Grant Recipient, Dr. Eduardo Nobile-Orazio
The 2019 GBS|CIDP Foundation Research Grant Recipient is Dr. Eduardo Nobile-Orazio, Associate Professor of Neurology, at Milan University, and Chair of the Neuromuscular and Neuroimmunology Service at Humanitas Clinical and Research Institute in Rozzano, Milan, Italy.
Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy
Published in The Lancet, May 7, 2019 Co-authored by Carina Bunschoten, Bart C Jacobs, Peter U K Van den Bergh, David R. Cornblath, Pieter A van Doorn
Dr. Bart Jacobs, Vice Chairman of GMAB, and co-authors, “Editor’s Choice,” Brain Journal
An article published in Brain Journal, September 25, 2018, regarding research findings of the International Guillain Barre Outcome Survey (IGOS), partially supported by GBS|CIDP Foundation International, received the “Editor’s Choice.” Findings of IGOS are significant to the GBS community as noted in the abstract summary of article
CIDP Disease Burden — Results of a US Nationwide Patient Survey
In 2017, a nationwide survey of US CIDP patients was conducted to assess the impact of disease-related disability and treatment on lifestyle and work activities. Approximately 3250 individuals aged ≥18 years, recruited by the GBS|CIDP Foundation and self-reported to have CIDP, were invited to complete an online survey; of these, 475 completed the survey and…
New GBS|CIDP Patient Registry Launching on Rare Disease Day!
This Rare Disease Day (February 28), the GBS|CIDP Foundation will be launching an online Patient Registry for patients with GBS|CIDP or variants of the condition
Research in CIDP: Are we making progress?
By Jeffrey A. Allen, MDMember, GBS|CIDP Foundation Global Medical Advisory Board CIDP as a named disease entity is now about 4 decades old. The laboratory data that helps define the disease, nerve conduction studies and in some cases cerebral spinal fluid and nerve biopsy, is even older; and the initial description of what has now…
Subcutaneous Immunoglobulin: A Newly Approved Treatment Option for CIDP
David Saperstein, MD Co-Director GBS/CIDP Center of Excellence Phoenix Neurological Associates Phoenix, AZ Intravenous immunoglobulin (IVIg) is one of the main therapies used to treat CIDP. This therapy can be very effective but there are drawbacks. Some people experience headaches related to the intravenous infusions. Some people have difficulty with IV access. Also, the need…
2018 Research Grant Finalists Announced
We are pleased to announce our 2018 Research Grant Awardees.
Attention Researchers! GBS Deemed Eligible for Research Studies through Department of Defense Peer Review
In March 2018 Congress passed an omnibus bill that finalized Fiscal Year 2018 appropriations. Guillain-Barré Syndrome was again listed as a condition eligible for study! Now is the time to begin applications for available grants. Below is more detailed information regarding applications and possible awards.
A Life and Legacy Dedicated to Research
On June 10, 2018 the GBS|CIDP Foundation International will be holding its 5th Annual New Jersey Walk & Roll. The event will be chaired by local resident, and Foundation volunteer, Susan Salzmann. Recently we had the pleasure of sitting down with Susan as she shared the complex story of her husband’s personal journey with CIDP….